WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406361
Description: NU1085 is a potent poly(ADP-ribose) polymerase (PARP) inhibitors have been developed that potentiate the cytotoxicity of ionizing radiation and anticancer drugs. The biological effects of NU1085 [Ki = 6 nM], in combination with temozolomide (TM) or topotecan (TP) have been studied in 12 human tumor cell lines (lung, colon, ovary, and breast cancer). Cells were treated with increasing concentrations of TM or TP +/- NU1085 (10 microM) for 72 h.
MedKoo Cat#: 406361
Chemical Formula: C14H11N3O2
Exact Mass: 253.08513
Molecular Weight: 253.26
Elemental Analysis: C, 66.40; H, 4.38; N, 16.59; O, 12.63
NU1085, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: NU1085; NU-1085; NU 1085.
IUPAC/Chemical Name: 2-(4-hydroxyphenyl)-1H-benzo[d]imidazole-7-carboxamide
InChi Key: KOUGHMOSYJCJLE-UHFFFAOYSA-N
InChi Code: InChI=1S/C14H11N3O2/c15-13(19)10-2-1-3-11-12(10)17-14(16-11)8-4-6-9(18)7-5-8/h1-7,18H,(H2,15,19)(H,16,17)
SMILES Code: O=C(C1=C2NC(C3=CC=C(O)C=C3)=NC2=CC=C1)N
The following data is based on the product molecular weight 253.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, Durkacz BW, Hostomsky Z, Newell DR. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res. 2000 Jul;6(7):2860-7. PubMed PMID: 10914735.